<DOC>
	<DOCNO>NCT02677727</DOCNO>
	<brief_summary>This prospective observational study investigate incidence , characteristic , change chronic neuropathy symptom relate cisplatin use EORTC CIPN-20 instrument . Approximately 60 patient collect study . The duration study 18 month patient . This study complement current R01 fund trial ( Platinum Study ) evaluate genetic predisposition chronic neuropathy 12 month chemotherapy . However , although platinum study evaluate similar patient population , evaluate natural history platinum induce neuropathy active treatment first 12 month post chemotherapy . This trial fill gap add investigator knowledge natural history genetic predisposition platinum neurotoxicity .</brief_summary>
	<brief_title>Study Cisplatin-Induced Peripheral Neuropathy Patients With Germ Cell Tumor</brief_title>
	<detailed_description>Primary Objective : To describe incidence characteristic , change , chronic neuropathy symptom related cisplatin , use EORTC CIPN-20 instrument Procedures : The EORTC QLQ-CIPN20 questionnaire complete day one cycle chemotherapy , every three week ( +/-7 day ) every 2 month ( +/- 30 day ) last dose chemotherapy . Patients ask complete questionnaire clinic routine visit . As part study , DNA blood sample collect stored Indiana Biobank Day 1 Cycle 1 .</detailed_description>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Inclusion criterion : 1 . 15 year age old time inform consent 2 . Have confirm pathologic and/or tumor marker diagnosis testicular extragonadal germ cell cancer . 3 . Provide write informed consent assent ( applicable ) . 4 . Ability complete questionnaire ( ) English assistance . 5 . Willing provide 10 mL blood sample future DNA test 6 . Planning receive least 3 cycle cisplatin ( 20 mg/m2/d 5 day ) base chemotherapy . 7 . Must agree continue clinical followup study cancer center . Exclusion criterion : 1 . Diagnosis ( current previous ) peripheral neuropathy ( diabetes cause ) . 2 . Previous exposure neurotoxic chemotherapy drug include taxanes , platinum agent , vinca alkaloid , epothilones . 3 . Salvage chemotherapy treatment bone marrow transplant . Salvage chemotherapy define treatment relapse disease follow initial chemotherapy treatment .</criteria>
	<gender>Male</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cisplatin-based chemotherapy</keyword>
	<keyword>Chemotherapy-induced peripheral neuropathy</keyword>
</DOC>